On January 2, Anavex announced results from its Phase 2/3 EXCELLENCE clinical trial for its candidate ANAVEX®2-73 in pediatric patients with Rett syndrome. The study failed to show statistical significance towards its primary endpoints, causing shares of Anavex Life Sciences Corp. stock to drop approximately 35%.
Contact our attorneys for a no-cost case evaluation.